Skip to main content
Top
Published in: Gastric Cancer 1/2017

01-03-2017 | Review Article

Mechanisms for the induction of gastric cancer by Helicobacter pylori infection: aberrant DNA methylation pathway

Authors: Masahiro Maeda, Hiroshi Moro, Toshikazu Ushijima

Published in: Gastric Cancer | Special Issue 1/2017

Login to get access

Abstract

Multiple pathogenic mechanisms by which Helicobacter pylori infection induces gastric cancer have been established in the last two decades. In particular, aberrant DNA methylation is induced in multiple driver genes, which inactivates them. Methylation profiles in gastric cancer are associated with specific subtypes, such as microsatellite instability. Recent comprehensive and integrated analyses showed that many cancer-related pathways are more frequently altered by aberrant DNA methylation than by mutations. Aberrant DNA methylation can even be present in noncancerous gastric mucosae, producing an “epigenetic field for cancerization.” Mechanistically, H. pylori-induced chronic inflammation, but not H. pylori itself, plays a direct role in the induction of aberrant DNA methylation. The expression of three inflammation-related genes, Il1b, Nos2, and Tnf, is highly associated with the induction of aberrant DNA methylation. Importantly, the degree of accumulated aberrant DNA methylation is strongly correlated with gastric cancer risk. A recent multicenter prospective cohort study demonstrated the utility of epigenetic cancer risk diagnosis for metachronous gastric cancer. Suppression of aberrant DNA methylation by a demethylating agent was shown to inhibit gastric cancer development in an animal model. Induction of aberrant DNA methylation is the major pathway by which H. pylori infection induces gastric cancer, and this can be utilized for translational opportunities.
Literature
3.
go back to reference Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med. 2007;13(4):470–6. doi:10.1038/nm1566 (Epub 2007/04/03). Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med. 2007;13(4):470–6. doi:10.​1038/​nm1566 (Epub 2007/04/03).
4.
go back to reference Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res. 2010;70(4):1430–40. doi:10.1158/0008-5472.can-09-2755 (Epub 2010/02/04). Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res. 2010;70(4):1430–40. doi:10.​1158/​0008-5472.​can-09-2755 (Epub 2010/02/04).
6.
go back to reference Yoda Y, Takeshima H, Niwa T, Kim JG, Ando T, Kushima R, et al. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer. 2015;18(1):65–76. doi:10.1007/s10120-014-0348-0 (Epub 2014/02/11).CrossRefPubMed Yoda Y, Takeshima H, Niwa T, Kim JG, Ando T, Kushima R, et al. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer. 2015;18(1):65–76. doi:10.​1007/​s10120-014-0348-0 (Epub 2014/02/11).CrossRefPubMed
7.
go back to reference Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res. 2006;12(3 Pt 1):989–95. doi:10.1158/1078-0432.ccr-05-2096 (Epub 2006/02/10). Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res. 2006;12(3 Pt 1):989–95. doi:10.​1158/​1078-0432.​ccr-05-2096 (Epub 2006/02/10).
8.
go back to reference Nakajima T, Maekita T, Oda I, Gotoda T, Yamamoto S, Umemura S, et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomark Prev. 2006;15(11):2317–21. doi:10.1158/1055-9965.epi-06-0436 (Epub 2006/11/23).CrossRef Nakajima T, Maekita T, Oda I, Gotoda T, Yamamoto S, Umemura S, et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomark Prev. 2006;15(11):2317–21. doi:10.​1158/​1055-9965.​epi-06-0436 (Epub 2006/11/23).CrossRef
9.
go back to reference Niwa T, Toyoda T, Tsukamoto T, Mori A, Tatematsu M, Ushijima T. Prevention of Helicobacter pylori-induced gastric cancers in gerbils by a DNA demethylating agent. Cancer Prev Res (Philadelphia, PA). 2013;6(4):263–70. doi:10.1158/1940-6207.capr-12-0369 (Epub 2013/04/06). Niwa T, Toyoda T, Tsukamoto T, Mori A, Tatematsu M, Ushijima T. Prevention of Helicobacter pylori-induced gastric cancers in gerbils by a DNA demethylating agent. Cancer Prev Res (Philadelphia, PA). 2013;6(4):263–70. doi:10.​1158/​1940-6207.​capr-12-0369 (Epub 2013/04/06).
10.
go back to reference Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6(5):963–8 (Epub 1953/09/01).CrossRefPubMed Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6(5):963–8 (Epub 1953/09/01).CrossRefPubMed
11.
go back to reference Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46(6):573–82. doi:10.1038/ng.2983 (Epub 2014/05/13).CrossRefPubMed Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46(6):573–82. doi:10.​1038/​ng.​2983 (Epub 2014/05/13).CrossRefPubMed
12.
13.
go back to reference Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999;59(21):5438–42 (Epub 1999/12/20).PubMed Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999;59(21):5438–42 (Epub 1999/12/20).PubMed
14.
go back to reference Kang GH, Lee S, Kim WH, Lee HW, Kim JC, Rhyu MG, et al. Epstein–Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol. 2002;160(3):787–94. doi:10.1016/s0002-9440(10)64901-2 (Epub 2002/03/14). Kang GH, Lee S, Kim WH, Lee HW, Kim JC, Rhyu MG, et al. Epstein–Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol. 2002;160(3):787–94. doi:10.​1016/​s0002-9440(10)64901-2 (Epub 2002/03/14).
15.
go back to reference Matsusaka K, Kaneda A, Nagae G, Ushiku T, Kikuchi Y, Hino R, et al. Classification of Epstein–Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res. 2011;71(23):7187–97. doi:10.1158/0008-5472.can-11-1349 (Epub 2011/10/13). Matsusaka K, Kaneda A, Nagae G, Ushiku T, Kikuchi Y, Hino R, et al. Classification of Epstein–Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res. 2011;71(23):7187–97. doi:10.​1158/​0008-5472.​can-11-1349 (Epub 2011/10/13).
16.
go back to reference Chan AO, Lam SK, Wong BC, Wong WM, Yuen MF, Yeung YH, et al. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut. 2003;52(4):502–6 (Epub 2003/03/13). Chan AO, Lam SK, Wong BC, Wong WM, Yuen MF, Yeung YH, et al. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut. 2003;52(4):502–6 (Epub 2003/03/13).
18.
go back to reference Miyazaki T, Murayama Y, Shinomura Y, Yamamoto T, Watabe K, Tsutsui S, et al. E-cadherin gene promoter hypermethylation in H. pylori-induced enlarged fold gastritis. Helicobacter. 2007;12(5):523–31. doi:10.1111/j.1523-5378.2007.00519.x (Epub 2007/09/01). Miyazaki T, Murayama Y, Shinomura Y, Yamamoto T, Watabe K, Tsutsui S, et al. E-cadherin gene promoter hypermethylation in H. pylori-induced enlarged fold gastritis. Helicobacter. 2007;12(5):523–31. doi:10.​1111/​j.​1523-5378.​2007.​00519.​x (Epub 2007/09/01).
19.
go back to reference Perri F, Cotugno R, Piepoli A, Merla A, Quitadamo M, Gentile A, et al. Aberrant DNA methylation in non-neoplastic gastric mucosa of H. pylori infected patients and effect of eradication. Am J Gastroenterol. 2007;102(7):1361–71. doi:10.1111/j.1572-0241.2007.01284.x Epub 2007/05/19). Perri F, Cotugno R, Piepoli A, Merla A, Quitadamo M, Gentile A, et al. Aberrant DNA methylation in non-neoplastic gastric mucosa of H. pylori infected patients and effect of eradication. Am J Gastroenterol. 2007;102(7):1361–71. doi:10.​1111/​j.​1572-0241.​2007.​01284.​x Epub 2007/05/19).
20.
go back to reference Nakajima T, Enomoto S, Yamashita S, Ando T, Nakanishi Y, Nakazawa K, et al. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J Gastroenterol. 2010;45(1):37–44. doi:10.1007/s00535-009-0142-7 (Epub 2009/10/13). Nakajima T, Enomoto S, Yamashita S, Ando T, Nakanishi Y, Nakazawa K, et al. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J Gastroenterol. 2010;45(1):37–44. doi:10.​1007/​s00535-009-0142-7 (Epub 2009/10/13).
21.
go back to reference Chan AO, Peng JZ, Lam SK, Lai KC, Yuen MF, Cheung HK, et al. Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation. Gut. 2006;55(4):463–8. doi:10.1136/gut.2005.077776 (Epub 2006/01/24). Chan AO, Peng JZ, Lam SK, Lai KC, Yuen MF, Cheung HK, et al. Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation. Gut. 2006;55(4):463–8. doi:10.​1136/​gut.​2005.​077776 (Epub 2006/01/24).
23.
go back to reference Nakajima T, Yamashita S, Maekita T, Niwa T, Nakazawa K, Ushijima T. The presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae. Int J Cancer. 2009;124(4):905–10. doi:10.1002/ijc.24018 (Epub 2008/11/28). Nakajima T, Yamashita S, Maekita T, Niwa T, Nakazawa K, Ushijima T. The presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae. Int J Cancer. 2009;124(4):905–10. doi:10.​1002/​ijc.​24018 (Epub 2008/11/28).
24.
go back to reference Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. 2007;39(2):232–6. doi:10.1038/ng1950 (Epub 2007/01/04).CrossRefPubMed Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. 2007;39(2):232–6. doi:10.​1038/​ng1950 (Epub 2007/01/04).CrossRefPubMed
25.
go back to reference Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, et al. Epigenetic stem cell signature in cancer. Nat Genet. 2007;39(2):157–8. doi:10.1038/ng1941 (Epub 2007/01/04).CrossRefPubMed Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, et al. Epigenetic stem cell signature in cancer. Nat Genet. 2007;39(2):157–8. doi:10.​1038/​ng1941 (Epub 2007/01/04).CrossRefPubMed
27.
go back to reference Takeshima H, Ikegami D, Wakabayashi M, Niwa T, Kim YJ, Ushijima T. Induction of aberrant trimethylation of histone H3 lysine 27 by inflammation in mouse colonic epithelial cells. Carcinogenesis. 2012;33(12):2384–90. doi:10.1093/carcin/bgs294 (Epub 2012/09/15).CrossRefPubMed Takeshima H, Ikegami D, Wakabayashi M, Niwa T, Kim YJ, Ushijima T. Induction of aberrant trimethylation of histone H3 lysine 27 by inflammation in mouse colonic epithelial cells. Carcinogenesis. 2012;33(12):2384–90. doi:10.​1093/​carcin/​bgs294 (Epub 2012/09/15).CrossRefPubMed
28.
go back to reference Kikuyama M, Takeshima H, Kinoshita T, Okochi-Takada E, Wakabayashi M, Akashi-Tanaka S, et al. Development of a novel approach, the epigenome-based outlier approach, to identify tumor-suppressor genes silenced by aberrant DNA methylation. Cancer Lett. 2012;322(2):204–12. doi:10.1016/j.canlet.2012.03.016 (Epub 2012/03/22).CrossRefPubMed Kikuyama M, Takeshima H, Kinoshita T, Okochi-Takada E, Wakabayashi M, Akashi-Tanaka S, et al. Development of a novel approach, the epigenome-based outlier approach, to identify tumor-suppressor genes silenced by aberrant DNA methylation. Cancer Lett. 2012;322(2):204–12. doi:10.​1016/​j.​canlet.​2012.​03.​016 (Epub 2012/03/22).CrossRefPubMed
29.
go back to reference Hur K, Niwa T, Toyoda T, Tsukamoto T, Tatematsu M, Yang HK, et al. Insufficient role of cell proliferation in aberrant DNA methylation induction and involvement of specific types of inflammation. Carcinogenesis. 2011;32(1):35–41. doi:10.1093/carcin/bgq219 (Epub 2010/10/29).CrossRefPubMed Hur K, Niwa T, Toyoda T, Tsukamoto T, Tatematsu M, Yang HK, et al. Insufficient role of cell proliferation in aberrant DNA methylation induction and involvement of specific types of inflammation. Carcinogenesis. 2011;32(1):35–41. doi:10.​1093/​carcin/​bgq219 (Epub 2010/10/29).CrossRefPubMed
30.
go back to reference Katsurano M, Niwa T, Yasui Y, Shigematsu Y, Yamashita S, Takeshima H, et al. Early-stage formation of an epigenetic field defect in a mouse colitis model, and non-essential roles of T- and B-cells in DNA methylation induction. Oncogene. 2012;31(3):342–51. doi:10.1038/onc.2011.241 (Epub 2011/06/21).CrossRefPubMed Katsurano M, Niwa T, Yasui Y, Shigematsu Y, Yamashita S, Takeshima H, et al. Early-stage formation of an epigenetic field defect in a mouse colitis model, and non-essential roles of T- and B-cells in DNA methylation induction. Oncogene. 2012;31(3):342–51. doi:10.​1038/​onc.​2011.​241 (Epub 2011/06/21).CrossRefPubMed
31.
go back to reference Ushijima T. Epigenetic field for cancerization. J Biochem Mol Biol. 2007;40(2):142–50 (Epub 2007/03/31).PubMed Ushijima T. Epigenetic field for cancerization. J Biochem Mol Biol. 2007;40(2):142–50 (Epub 2007/03/31).PubMed
32.
go back to reference Ando T, Yoshida T, Enomoto S, Asada K, Tatematsu M, Ichinose M, et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer. 2009;124(10):2367–74. doi:10.1002/ijc.24219 (Epub 2009/01/24).CrossRefPubMed Ando T, Yoshida T, Enomoto S, Asada K, Tatematsu M, Ichinose M, et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer. 2009;124(10):2367–74. doi:10.​1002/​ijc.​24219 (Epub 2009/01/24).CrossRefPubMed
33.
go back to reference Nanjo S, Asada K, Yamashita S, Nakajima T, Nakazawa K, Maekita T, et al. Identification of gastric cancer risk markers that are informative in individuals with past H. pylori infection. Gastric Cancer. 2012;15(4):382–8. doi:10.1007/s10120-011-0126-1 (Epub 2012/01/13). Nanjo S, Asada K, Yamashita S, Nakajima T, Nakazawa K, Maekita T, et al. Identification of gastric cancer risk markers that are informative in individuals with past H. pylori infection. Gastric Cancer. 2012;15(4):382–8. doi:10.​1007/​s10120-011-0126-1 (Epub 2012/01/13).
34.
go back to reference Asada K, Nakajima T, Shimazu T, Yamamichi N, Maekita T, Yokoi C, et al. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut. 2015;64(3):388–96. doi:10.1136/gutjnl-2014-307094 (Epub 2014/11/08).CrossRefPubMed Asada K, Nakajima T, Shimazu T, Yamamichi N, Maekita T, Yokoi C, et al. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut. 2015;64(3):388–96. doi:10.​1136/​gutjnl-2014-307094 (Epub 2014/11/08).CrossRefPubMed
35.
go back to reference Asada K, Nakajima T, Shimazu T, Yamamichi N, Maekita T, Yokoi C, et al. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut. 2014. doi:10.1136/gutjnl-2014-307094. Asada K, Nakajima T, Shimazu T, Yamamichi N, Maekita T, Yokoi C, et al. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut. 2014. doi:10.​1136/​gutjnl-2014-307094.
36.
Metadata
Title
Mechanisms for the induction of gastric cancer by Helicobacter pylori infection: aberrant DNA methylation pathway
Authors
Masahiro Maeda
Hiroshi Moro
Toshikazu Ushijima
Publication date
01-03-2017
Publisher
Springer Japan
Published in
Gastric Cancer / Issue Special Issue 1/2017
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-016-0650-0

Other articles of this Special Issue 1/2017

Gastric Cancer 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine